Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia vs Mesalamine for Crohn's Disease Recurrence Post-Ileocolectomy
NCT01696942Phase 4Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Feb 2013
- Primary completion
- Jun 2016
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of certolizumab pegol in Crohn's disease, sponsored by Penn State Health Milton S. Hershey Medical Center. Started Feb 2013; status: terminated.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01696942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696942.